Guy M. Goodwin
YOU?
Author Swipe
View article: Estimated Vaccine Effectiveness for Respiratory Syncytial Virus–Related Acute Respiratory Illness in Older Adults: Findings From the First Postlicensure Season
Estimated Vaccine Effectiveness for Respiratory Syncytial Virus–Related Acute Respiratory Illness in Older Adults: Findings From the First Postlicensure Season Open
Background Respiratory syncytial virus (RSV) is an important cause of severe respiratory illness among older adults. Previously, we showed that the RSVpreF vaccine (Abrysvo; Pfizer) prevents RSV-related lower respiratory tract disease–rela…
View article: Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial
Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial Open
Background: Post-traumatic stress disorder (PTSD) is a debilitating condition for which there are few efficacious treatments. Psilocybin is being studied for use in treatment-resistant depression but has not yet been investigated in PTSD. …
View article: 670. CAN WE RE-MEDICALISE THE PSYCHEDELIC EXPERIENCE?
670. CAN WE RE-MEDICALISE THE PSYCHEDELIC EXPERIENCE? Open
Background Despite the widespread availability of multiple antidepressant treatments, depression remains a common and sometimes debilitating disorder. A significant proportion of patients with major depressive disorder fail two or more ant…
View article: Building virtual patients for training mental health professionals
Building virtual patients for training mental health professionals Open
We present a framework for developing “virtual patients” to augment training for Mental Health Professionals (MHPs) with a process that is more scalable and systematic than current practice which relies on human role-play for the training …
View article: Building virtual patients for training mental health professionals
Building virtual patients for training mental health professionals Open
We present a framework for developing “virtual patients” to augment training for Mental Health Professionals (MHPs) with a process that is more scalable and systematic than current practice which relies on human role-play for the training …
View article: 165. Real-world Abrysvo Vaccine Effectiveness (VE) against Respiratory Syncytial Virus (RSV)-related Severe Acute Respiratory Infection (ARI) Hospitalizations and Emergency Department (ED) Visits—Kaiser Permanente of Southern California (KPSC), November 2023–April 2024
165. Real-world Abrysvo Vaccine Effectiveness (VE) against Respiratory Syncytial Virus (RSV)-related Severe Acute Respiratory Infection (ARI) Hospitalizations and Emergency Department (ED) Visits—Kaiser Permanente of Southern California (KPSC), November 2023–April 2024 Open
Background Abrysvo’s pivotal trial analysis of efficacy against severe RSV-related respiratory disease was hampered by accrual of few hospitalizations/ED events. In this post-licensure study, we evaluated Abrysvo VE against 1st RSV-related…
View article: P-56. Respiratory Syncytial Virus (RSV) Vaccine Uptake among Adults ≥60 years old in a Large Integrated Healthcare System in the U.S
P-56. Respiratory Syncytial Virus (RSV) Vaccine Uptake among Adults ≥60 years old in a Large Integrated Healthcare System in the U.S Open
Background In 2023, the FDA approved two new vaccines to protect adults ≥ 60 years old from severe RSV disease. CDC’s Advisory Committee on Immunization Practices recommended a shared decision-making approach between age-eligible adults an…
View article: P-604. Preliminary real-world Abrysvo vaccine effectiveness (VE) against Respiratory Syncytial Virus (RSV)-related lower respiratory tract disease (LRTD) hospitalizations and emergency department (ED) visits—Kaiser Permanente of Southern California (KPSC), November 2023-April 2024
P-604. Preliminary real-world Abrysvo vaccine effectiveness (VE) against Respiratory Syncytial Virus (RSV)-related lower respiratory tract disease (LRTD) hospitalizations and emergency department (ED) visits—Kaiser Permanente of Southern California (KPSC), November 2023-April 2024 Open
Background While the pivotal randomized clinical trial documented the efficacy of the RSVpreF vaccine (Abrysvo) against RSV-related LRTD, the limited number of hospitalizations and ED visits hampered VE assessment for these clinical outcom…
View article: A single dose of lamotrigine induces a positive memory bias in healthy volunteers
A single dose of lamotrigine induces a positive memory bias in healthy volunteers Open
Background Lamotrigine has been shown to be effective in the long-term treatment and relapse prevention of depression in bipolar disorder. However, the neuropsychological mechanisms underlying these effects are unclear. We investigated the…
View article: The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression
The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression Open
The intensity of psychedelic experience overlaps widely across doses and mitigates the risk of unblinding to dose. Correlations between psychedelic experience and outcome suggest specificity in psilocybin's mechanism of action. Quality and…
View article: Estimated Vaccine Effectiveness for Respiratory Syncytial Virus–Related Lower Respiratory Tract Disease
Estimated Vaccine Effectiveness for Respiratory Syncytial Virus–Related Lower Respiratory Tract Disease Open
Importance Clinical trials have demonstrated high vaccine efficacy (VE) against lower respiratory tract disease (LRTD) but enrolled a smaller proportion of persons aged 75 years or older and those with comorbidities than seen in highest-ri…
View article: Psychedelics in developmental stuttering to modulate brain functioning: a new therapeutic perspective?
Psychedelics in developmental stuttering to modulate brain functioning: a new therapeutic perspective? Open
Developmental stuttering (DS) is a neurodevelopmental speech-motor disorder characterized by symptoms such as blocks, repetitions, and prolongations. Persistent DS often has a significant negative impact on quality of life, and interventio…
View article: Knowledge gaps in psychedelic medicalisation: Clinical studies and regulatory aspects
Knowledge gaps in psychedelic medicalisation: Clinical studies and regulatory aspects Open
Psychedelic drugs including psilocybin and LSD are undergoing clinical trials for a range of psychiatric and neurological conditions, and have particularly shown substantial promise in phase 2 studies of depression. In this article we outl…
View article: Comorbid physical health burden of serious mental health disorders in 32 European countries
Comorbid physical health burden of serious mental health disorders in 32 European countries Open
Background Mental health disorders (MHDs) are associated with physical health disparities, but underlying excess risk and health burden have not yet been comprehensively assessed. Objective To assess the burden of comorbid physical health …
View article: A single dose of lamotrigine induces a positive memory bias in healthy volunteers
A single dose of lamotrigine induces a positive memory bias in healthy volunteers Open
Background Lamotrigine has been shown to be effective in the long-term treatment and relapse prevention of depression in bipolar disorder. However, the neuropsychological mechanisms underlying these effects are unclear. We investigated the…
View article: Excess physical disease burden associated with selected mental health disorders in Europe
Excess physical disease burden associated with selected mental health disorders in Europe Open
Introduction People with mental health disorders (MHDs) have worse physical health compared to the general population. To date, no comprehensive epidemiological overview exists and the extent of the excess public health burden is unknown. …
View article: The psychedelic experience and treatment‐resistant depression
The psychedelic experience and treatment‐resistant depression Open
Interest in the use of serotonergic agonists such as psilocybin in treatment-resistant depression (TRD) has grown more quickly than the evidence on which to base a final opinion, as emphasized by McIntyre et al1 in their review. Psilocybin…
View article: Psilocybin therapy for treatment resistant depression: prediction of clinical outcome by natural language processing
Psilocybin therapy for treatment resistant depression: prediction of clinical outcome by natural language processing Open
Rationale Therapeutic administration of psychedelics has shown significant potential in historical accounts and recent clinical trials in the treatment of depression and other mood disorders. A recent randomized double-blind phase-IIb stud…
View article: From a Large Language Model to Three-Dimensional Sentiment
From a Large Language Model to Three-Dimensional Sentiment Open
We present an automated model of sentiment which assigns to any arbitrary text three values: valence, arousal, and confidence (VAC) and is based on the three-dimensional framework of emotion introduced by Mehrabian and Russell [1]. While s…
View article: Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication
Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication Open
Psilocybin is being investigated as a treatment in adults with treatment-resistant depression (TRD). Withdrawal from serotonergic antidepressant drugs is a common prerequisite for taking part in trials of psilocybin due to the possibility …
View article: Improvement in Depression Symptoms Measured by Montgomery-Åsberg Depression Rating Scale and Quick Inventory of Depressive Symptomatology-Self Rated Items after Randomised Double-blind COMP360 Psilocybin Therapy for Treatment-resistant Depression
Improvement in Depression Symptoms Measured by Montgomery-Åsberg Depression Rating Scale and Quick Inventory of Depressive Symptomatology-Self Rated Items after Randomised Double-blind COMP360 Psilocybin Therapy for Treatment-resistant Depression Open
Introduction COMP360 is a synthetic, proprietary, purified form of psilocybin in development for treatment-resistant depression (TRD) with FDA Breakthrough Therapy designation. In a recent phase IIb study, COMP360 psilocybin 25mg was super…